๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenzhen

576 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha
2022-03-15
Active, closed
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
NCT05285826Papillomavirus Infections
Drug9vHPV vaccine
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Active, closed
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT05144243Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 4
44
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Xiangyang, Suzhou, Nanchang
2022-01-06
Recruiting
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
NCT05498974Type1diabetes, Diabetes
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Active, closed
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
NCT05203679Hemophilia B
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Recruiting
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
NCT05553886Chronic Heart Failure With Reduced Ejection Fraction
Shenzhen People's Hospital
Phase 3
5
Shenzhen
2021-12-21
Active, closed
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858Generalized Myasthenia Gravis
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
288
Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha
2021-12-14
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919Heart Failure
China National Center for Cardiovascular Diseases
Not applicable
160
Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai
2021-12-12
Active, closed
Long-term Efficacy and Safety Study of GV-971
NCT05181475Alzheimer Disease
DrugSodium Oligomannate
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Recruiting
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
NCT04136535NSCLC Stage IV
Fudan University
Phase 2
105
Shenzhen
2021-11-18
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
DrugEfgartigimod PH20
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Active, closed
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
61
Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi
2021-11-04
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
NCT05485948Polycythemia Vera
DrugRopeginterferon alfa-2b
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsAsciminib·Bosutinib·Nilotinib·Dasatinib
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
DrugsElranatamab·Pomalidomide·Daratumumab·Dexamethasone
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Recruiting
PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer
NCT05033392Stomach Neoplasms
Wan He
Phase 2
62
Shenzhen
2021-09-14
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
Active, closed
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
NCT04968028Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Shanghai Changzheng Hospital
Not applicable
167
Beijing, Shenzhen, Harbin, Jining, Qingdao, Shanghai, Taiyuan, Xiโ€™an
2021-08-17
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
DrugPenpulimab
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Active, closed
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
NCT04946734PFO - Patent Foramen Ovale, Migraine
Guangdong Provincial People's Hospital
Phase 3
440
Xiamen, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhanjiang, Nanning, Shangqiu
2021-08-12
Active, closed
Newly Diagnosed Glioblastoma
NCT04959500Glioblastoma
DrugsAnlotinib hydrochloride·Temozolomide
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Active, closed
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567Lupus Erythematosus, Systemic
DrugLitifilimab
Biogen
Phase 3
562
Beijing, Dongguan, Guangzhou, Shenzhen, Haikou, Changsha, Zhuzhou, Wuhan
2021-07-16
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFฮฑ Inhibitor Treatment
NCT04908189Psoriatic Arthritis
DrugsApremilast·Deucravacitinib
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Active, closed
Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients
NCT04538911Tuberculosis
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 1
60
Shenzhen
2021-07-02
Active, closed
Characteristics of Vaginal and Intestinal Microbiota and Cervical HPV Infection
NCT05003505Intestinal Microbiota, Vaginal Microbiota, HPV Infection
Fujian Maternity and Child Health Hospital
Observational
651
Fuzhou, Ningde, Quanzhou, Xiamen, Zhangzhou, Foshan, Shenzhen, Wuhan
2021-07-01
Active, closed
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer
DrugsMRTX849·Erbitux·MFOLFOX6·Folfiri
Mirati Therapeutics Inc.
Phase 3
461
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-24
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsXeloda·Liposomal doxorubicin·Taxol·Abraxane
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Active, closed
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
NCT05058040Alzheimer Disease
DrugSodium Oligomannate
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
2,500
Hefei, Beijing, Chongqing, Xianmencun, Dongguan, Guangzhou, Shenzhen, Zhuhai
2021-06-02
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Beijing, Lanzhou, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Suzhou, Nanchang
2021-05-24
Active, closed
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
NCT04848753Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Recruiting
Greater-Bay-Area Healthy Aging Brain Study (GHABS)
NCT06183658Alzheimer's Disease
Shenzhen Bay Laboratory
Observational
1,400
Shenzhen
2021-05-01
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
NCT04794972Recurrent Glioma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Changzhou
2021-04-01
Active, closed
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136Systemic Lupus Erythematosus
DrugPaclitaxel
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Recruiting
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
NCT06069232Aortic Valve Disease
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242Pediatric Migraine
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
By invitation
Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease
NCT07033676Hypertension, Heart Disease
The University of Hong Kong-Shenzhen Hospital
Observational
46
Shenzhen
2021-01-01
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naรฏve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
DrugsOlaparib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Recruiting
Safety and Efficacy Evaluation of ฮฒ-globin Restored Autologous Hematopoietic Stem Cells in ฮฒ-thalassemia Major Patients
NCT05745532ฮฒ-thalassemia
Shenzhen Hemogen
Phase EARLY_PHASE1
10
Shenzhen
2020-12-01
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
DrugDarolutamide
Bayer
Phase 3
402
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Recruiting
Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)
NCT06524427Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsOlaparib·Etoposide·Durvalumab·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
870
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-07-06
Recruiting
Assisting Pulmonary Disease Diagnosis With Ophthalmic Artificial Intelligence Technology
NCT05847894Pulmonary Diseases, Ophthalmological Diagnostic Techniques, Artificial Intelligence
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
10,000
Guangzhou, Shenzhen
2020-06-29
Recruiting
Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository
NCT04574089Vaginitis
Peking University Shenzhen Hospital
Phase 3
50
Shenzhen
2020-05-01
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Tianjin
2020-04-02
Active, closed
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
NCT04161898Takayasu Arteritis (TAK)
DrugsPrednisolone·Upadacitinib
AbbVie
Phase 3
56
Beijing, Guangzhou, Shenzhen, Shenyang, Shanghai
2020-02-04
Recruiting
A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis
NCT04771728Bacterial Vaginosis
Peking University Shenzhen Hospital
Phase 4
140
Shenzhen
2020-02-01
Active, closed
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
NCT04405557Early Detection of Cancer
Geneplus-Beijing Co. Ltd.
Observational
757
Beijing, Shenzhen, Zhengzhou, Changsha, Nanjing, Changchun, Jinzhou, Chengdu
2019-11-12
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (ฮฒ)-Thalassemia
NCT04143724Beta-Thalassemia
DrugACE-536
Celgene
Phase 2
99
Guangzhou, Shenzhen, Nanning, Chengdu
2019-11-07
Recruiting
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
DrugPaclitaxel
Peking University First Hospital
Observational
315
Beijing, Shenzhen, Baoding
2019-09-01
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Active, closed
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)
NCT03932136Clinical High Risk Syndrome of Psychosis
Shanghai Jiao Tong University School of Medicine
Phase 3
300
Guangzhou, Zhengzhou, Changsha, Suzhou, Shanghai, Shenzhen, Tianjin
2019-07-14
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Recruiting
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
NCT04162353Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma
iCell Gene Therapeutics
Phase 1
12
Shenzhen, Chengdu
2019-07-01
Recruiting
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients
NCT05061342Cancer
Fengming Kong
Observational
5,000
Shenzhen
2019-06-27
Active, closed
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307Asthma
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Active, closed
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
NCT03753685Nonsmall Cell Lung Cancer, Brain Metastases
Fudan University
Phase 2
27
Shenzhen
2019-04-12
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
DrugPembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Recruiting
Nanshan Elderly Cohort Study
NCT03569735Hypertension, Type 2 Diabetes Mellitus, Cardiovascular Diseases, Stroke
Sun Yat-sen University
Observational
20,000
Shenzhen, Guangzhou
2018-05-26
Recruiting
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298Metastatic Breast Cancer
Herui Yao
Phase 3
210
Guangzhou, Shantou, Shenzhen, Zhangjiang, Zhuhai, Nanning, Changsha
2018-05-01
Recruiting
Shenzhen Birth Cohort Study
NCT03830879Pregnancy Complications, Gestational Diabetes, Obstetric Labor Complications, Neurodevelopmental Disorders
Sun Yat-sen University
Observational
10,000
Shenzhen
2018-03-06
Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116Locally Advanced Solid Tumors, Metastatic Solid Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
500
Beijing, Daping, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Shatin
2017-03-07
Recruiting
Multicenter Cohort Study on Osteoporosis
NCT02958020Osteoporosis
Shanghai University of Traditional Chinese Medicine
Observational
50,000
Shenzhen, Ganzhou, Jinan, Kunming, Beijing, Changchun, Guangzhou, Lanzhou
2016-11
Active, closed
Sympathetic Mapping/ Ablation of Renal Nerves Trial
NCT02761811Hypertension
SyMap Medical (Suzhou), Ltd.
Not applicable
220
Beijing, Chongqing, Shenzhen, Shijiazhuang, Daqing, Wuhan, Nanjing, Xuzhou
2016-06-30
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Active, closed
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02568267Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
DrugEntrectinib
Hoffmann-La Roche
Phase 2
534
Harbin, Wuhan, Chengdu, Beijing, Guangzhou, Hangzhou, Shanghai, Shenzhen
2015-11-19
Active, closed
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
NCT02221999Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer, Inflammatory Breast Cancer
DrugsLetrozole·Cisplatin·Paclitaxel
RenJi Hospital
Phase 2/3
250
Shenzhen, Handan, Hengyang, Hohhot, Kunshan, Yinchuan, Shanghai, Zhoushan
2013-09
Recruiting
Registry of Multicenter Brain-Heart Comorbidity in China
NCT05961748Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure
Beijing Tiantan Hospital
Observational
100,000
Beijing, Fuzhou, Xiamen, Shenzhen, Harbin, Zhengzhou, Shanghai, Shanxi
2012-01-01
Rows per page Showing 501–576 of 576
Previous 4 5 6
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 576 of those studies with a site in Shenzhen.

How many clinical trials are recruiting in Shenzhen?

337 of the 576 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 115 have not yet opened recruitment, 109 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.